News|Articles|April 27, 2017

Phenobarbital Recalled Due to Labeling Error

Truxton, Inc. is voluntarily recalling one lot of Phenobarbital Tablets, USP, 15 mg because of a labeling error on declared strength.

Truxton, Inc. (Bellmawr, NJ) announced on April 21, 2017 that it was voluntarily recalling lot 70952A of phenobarbital tablets, USP, 15 mg after the company received a customer complaint that a bottle labeled as phenobarbital 15 mg contained phenobarbital 30 mg tablets. The recalled product, which is used as a sedative or anticonvulsant, was distributed nationwide in the United States to physician and veterinarian treatment centers and is packaged in 1000 count bottles, NDC 0463-6160-10, UPC 7 0463616010 6, lot number 70952A, expiration date 11/17.

The company warns that overdosing of the product may cause severe intoxication, which could lead to cardiogenic shock, renal failure, coma, or death. The company stated in a press release that it had not had any reports of adverse events related to the recall. Adverse events can be reported to FDA through the agency’s website.

Source: FDA


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.